Literature DB >> 12431872

Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams.

Josette Behra-Miellet1, Luc Dubreuil, Estelle Jumas-Bilak.   

Abstract

Minimal inhibitory concentrations of moxifloxacin were compared with those of ofloxacin, ciprofloxacin, clindamycin, metronidazole and six beta-lactams for 159 anaerobes isolated from human clinical samples. Unlike other fluoroquinolones, moxifloxacin demonstrated high activity against the 76 strains of the Bacteroides fragilis group as the minimal inhibitory concentration(50) was 0.5 mg/l. Porphyromonas, Prevotella, Fusobacterium and Gram-positive anaerobic cocci were inhibited by 1 mg/l or less of moxifloxacin. It inhibited 93.7, 94.9 and 98% of the 159 strains investigated at concentrations of 1, 2 and 4 mg/l, respectively. Moxifloxacin was more potent than ofloxacin and ciprofloxacin against Gram-positive rods and anaerobic cocci. Its broad anaerobic spectrum in vitro is promising for the treatment of intra-abdominal and respiratory infections.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12431872     DOI: 10.1016/s0924-8579(02)00209-1

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  5 in total

1.  Clinical and microbiological efficacy of moxifloxacin versus amoxicillin/clavulanic acid in severe odontogenic abscesses: a pilot study.

Authors:  B Al-Nawas; C Walter; T Morbach; N Seitner; E Siegel; M Maeurer; F Krummenauer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-29       Impact factor: 3.267

2.  Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.

Authors:  Elizabeth D Hermsen; Laurie B Hovde; Kelly A Sprandel; Keith A Rodvold; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 3.  Moxifloxacin: a review of its use in the management of bacterial infections.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections.

Authors:  Charles E Edmiston; Candace J Krepel; Gary R Seabrook; Lewis R Somberg; Atilla Nakeeb; Robert A Cambria; Jonathan B Towne
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

5.  Effect of antibiotic pre-treatment and pathogen challenge on the intestinal microbiota in mice.

Authors:  Tadasu Iizumi; Takako Taniguchi; Wataru Yamazaki; Geraldine Vilmen; Alexander V Alekseyenko; Zhan Gao; Guillermo I Perez Perez; Martin J Blaser
Journal:  Gut Pathog       Date:  2016-11-18       Impact factor: 4.181

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.